Gliomas are a complex group of brain and spinal cord tumors that start from glial cells, which are cells that…
Browsing: Brain
Vorasidenib (AG-881) is a promising targeted therapy for gliomas with IDH1 or IDH2 mutations. This novel approach could potentially revolutionize…
Vorasidenib, an oral, brain-penetrant, dual inhibitor of mutant IDH1/2 enzymes, shows promise in treating grade 2 gliomas. The INDIGO trial,…
Karan Dixit, MD, from Northwestern Medicine, delivered a compelling presentation during the Plenary Session at the recent conference on glioma…
Dr. Katherine Peters from Duke University Medical Center discussed the current treatments and their limitations for low-grade glioma patients with…
High-grade gliomas represent a significant burden in neuro-oncology, affecting thousands of individuals worldwide each year. Gliomas, a form of brain…
Dr. David Peereboom from Cleveland Clinic conducted a phase one clinical trial called CRUX to investigate the efficacy and safety…
The results of the CRUX study, which focused on the safety and feasibility of the JAK stat inhibitor Ruxolitinib in…
At the (ASCO) 2023 conference, Dr. Manmeet Singh Ahluwalla discussed, researchers presented the final trial report on a phase 1…
Brain metastases, or secondary brain tumors, occur when cancer cells spread from their original site to the brain. This devastating…
Decoding Recurrent Brain Metastases: The Power of 18F-Fluciclovine PET This discusses the challenges in detecting recurrent brain metastases and…
iFrame is not supported! VAL-083: Dennis Brown [2022]: Key Facts To Consider Glioblastoma VAL-083, or it’s chemical name dianhydrogalactitol…
VAL-083: Dennis Brown [2022]: Key Facts To Consider Glioblastoma VAL-083, or it’s chemical name dianhydrogalactitol (val-083), is a compound…
Julie Wu, MD, Ph.D., Medical Oncology Fellow at Stanford University. In this video, she speaks about the IASLC 2022 Abstract…
Julie Wu, MD, Ph.D., Medical Oncology Fellow at Stanford University. In this video, she speaks about the IASLC 2022 Abstract…
Dr. Schiff is the Harrison Distinguished Professor of Neurology, Neurological Surgery, and Medicine. He is the co-director of the UVA…
Dr. Schiff is the Harrison Distinguished Professor of Neurology, Neurological Surgery, and Medicine. He is the co-director of the UVA…
Erin Murphy, MD Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic speaks about ASTRO 2021 Abstract – 3258 Neurocognitive…
Erin Murphy, MD Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic speaks about ASTRO 2021 Abstract – 3258 Neurocognitive…
Samuel Chao, MD Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic speaks about the ASTRO 2021 Abstract – 51…
Samuel Chao, MD Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic speaks about the ASTRO 2021 Abstract – 51…
Yanhong Shi, Ph.D., Professor, Department of Developmental and Stem Cell Biology at City of Hope speaks about Targeting PUS7 Suppresses…
Sarah E. S. Leary, MD, Associate Professor, Center for Clinical and Translational Research, at the Seattle Children’s Hospital Research Foundation…
Sarah E. S. Leary, MD, Associate Professor, Center for Clinical and Translational Research, at the Seattle Children’s Hospital Research Foundation…
Yanhong Shi, Ph.D., Professor, Department of Developmental and Stem Cell Biology at City of Hope speaks about Targeting PUS7 Suppresses…
Jeff M. Michalski, MD, MBA, FASTRO, Professor of Radiation Oncology at Washington University and the Siteman Cancer Center speaks about…
Matthew Tate, MD, Ph.D., Associate Professor of Neurological Surgery and Neurology – Ken and Ruth Davee Department Northwestern University Feinberg…
Christine Brown, Ph.D. Deputy Director, T Cell Therapeutics Research Laboratory; Professor, Departments of Hematology and Hematopoietic Cell Transplantation and Immuno-Oncology…
Rimas V. Lukas, MD from Northwestern Medicine speaks about Nonmalignant Brain Tumors.Link to Abstract:https://journals.lww.com/continuum/Fulltext/2020/12000/Nonmalignant_Brain_Tumors.6.aspxSUMMARY:REVIEW’S OBJECTIVEMeningioma, pituitary adenoma, craniopharyngioma, and glioneuronal…
Santhosh Upadhyaya, MD, Pediatric Hematologist from St. Jude Children’s Research Hospital speaks about ATRT molecular groups: looking at the biology…
Amar Gajjar, MD from the Division of Neuro Oncology, Department of Oncology, St Jude Children’s Research Hospital discusses Outcomes by…
Jeffrey Skolnik, MD Inovio Pharmaceuticals discusses the Empower the Immune System to Treat Glioblastoma: DNA as Medicine.Information: Â * Explore DNA…
Prof. Matthias Preusser from the Medical University of Vienna discusses EANO guidelines on the diagnosis and treatment of diffuse gliomas…
Philadelphia, PA (December 15, 2020) – Oncoceutics, Inc. announced today the outlicense of the rights to the company’s lead compound,…
Philadelphia, PA (November 11, 2020) – Oncoceutics, Inc. announced that the latest research on imipridones ONC201 and ONC206 for the…
Philadelphia, PA (November 5, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, announced today that it has received…
Charles Limoli, Ph.D. of the University of California Irvine explains Cancer treatment without side effects? UCI, Swiss researchers eliminate brain…
Rahul Tendulkar, MD from the Cleveland Clinic explains the ASTRO 2020 abstract Impact of Post-Mastectomy Radiation Therapy (PMRT) in Women…
Samuel Chao, MD from the Cleveland Clinic, Case Comprehensive Cancer Center speaks about the ASTRO 2020 abstract 18F-Fluciclovine PET to…
Philadelphia, PA (October 12, 2020) – Oncoceutics, Inc. announced that the European Patent Office has issued a Decision to Grant…
Xiang Cheng Ph.D. and Feng Geng Ph.D. from Ohio State University Comprehensive Cancer Center discusses Blocking Fat Storage Might Offer…
Ammar Chaudhry, MD at City of Hope discusses an abstract from AACR 2020 entitled Randiomic prediction of survival in recurrent…
Minesh P Mehta MD, FASTRO @BaptistHealthSF High- vs Low-Dose Radiation for Adult Low-Grade Glioma
Hui Li, PhD at Univeristy of Virginia UVA IDs Gene Responsible for Deadly Glioblastoma Scientists have found an oncogene (a…
Jason P Sheehan, MD of the University of Virginia speaks about his final thoughts on the Focused Ultrasound Shows Potential…
Jason P Sheehan, MD of the University of Virginia explains how this will affect clinicians today, the Focused Ultrasound Shows…
Jason P Sheehan, MD of the University of Virginia discusses the common questions he receives about the Focused Ultrasound Shows…
Jason P Sheehan, MD of the University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor. The…
Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor
Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor
Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor
Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor
In this edition of The Onco’Zine Brief Peter Hofland talks with Catherine Ivy, the Founder and President of the Ben…
David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma…
David A. Reardon, MD Dana-Farber Cancer Institute discusses What is the rationale in combining these agents together? – INO-5401 and…
David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma…
Philadelphia, PA (July 21, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, announced today that the U.S. Food…
Philadelphia, PA (July 22, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates GBM Awareness Day this July…
Philadelphia, PA (May 28, 2020) – Oncoceutics, Inc. announced that it and its collaborators will present several abstracts at the…
Philadelphia, PA (May 5, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates Brain Tumor Awareness Month this…
Wenyin Shi, MD of Jefferson Health @TJUHospital #JeffersonHealth discusses the patients with newly diagnosed glioblastoma, initial experience with scalp saving…
Wenyin Shi, MD of Jefferson Health @TJUHospital #JeffersonHealth answers common questions asked on the patients with newly diagnosed glioblastoma, initial…
Philadelphia, PA (April 1, 2020) – Oncoceutics, Inc., announced that it was informed by its Japanese licensee, Ohara Pharmaceutical Co.,…
Philadelphia, PA (March 26, 2020) – Oncoceutics, Inc. announced that the Chinese National Intellectual Property Administration (CNIPA) has issued a…
Santosh Kesari, MD, PhD @DrKesari of @JohnWayneCI discusses a new clinical trial with the now approved drug, pemetrexed, for chordoma…
Santosh Kesari, MD, PhD @DrKesari of @JohnWayneCI discusses a new clinical trial with the now approved drug, pemetrexed, for chordoma…
Philadelphia, PA (January 27, 2020) – Oncoceutics announced that the National Brain Tumor Society (NBTS) has committed to providing more…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics explains how this is going to affect clinicians today and what clinicians should…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics answers what data has come out of the trial? _________ Oncoceutics, Inc. announced…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics answers how can we get access to this drug for glioblastoma? ___________ Oncoceutics,…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics discusses what’s next in ONC201 in adult recurrent glioblastoma. __________ Oncoceutics, Inc. announced…
Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics discusses the clinical efficacy of weekly ONC201 in adult recurrent glioblastoma. ________ Oncoceutics,…
Brain Tumor Center affiliated with Providence Saint John’s Health Center The approved lung cancer drug pemetrexed is at the center…
The Department of Neurosurgery at the Icahn School of Medicine at Mount Sinai has received more than $10 million in…
Philadelphia, PA (November 13, 2019) – Oncoceutics, Inc. announced that results from the second and third cohort of the Phase…
Akash J. Patel of @bcmhouston answers meningioma molecular profiling reliably predicts tumor recurrence: how does this help us? ________ Read…
Akash J. Patel of @bcmhouston explains meningioma molecular profiling reliably predicts tumor recurrence. __________ Read here: https://www.eurekalert.org/pub_releases/2019-10/bcom-mmp100719.php
Kailin Yang, MD of Cleveland Clinic answers how this will affect clinicians today and questions asked by his colleagues. _______…
Kailin Yang, MD of Cleveland Clinic discusses targeting metabolic reprogramming to radiosensitize glioblastoma stem cells. _________ Inhibiting two critical steps…
Philadelphia, PA (September 16, 2019) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates National Childhood Cancer Awareness Month…
Philadelphia, PA (September 10, 2019) – Oncoceutics, Inc. announced a scientific publication in the Journal of Neuro-Oncology describing a complete…
Philadelphia, PA (August 26, 2019) – Oncoceutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the…
Joshua Allen PhD @jallenphd Of Oncoceutics, Inc. Discusses Why Does This Subset Of Patients Respond To ONC201: It Appears To…
Joshua Allen PhD @jallenphd Of Oncoceutics, Inc. Discusses Other Suitable Combinations For This Agent That Could Help More People: Which…
Joshua Allen PhD @jallenphd Of Oncoceutics, Inc. Discusses Latest Data For Patients Treated With ONC201 With H3 K27M-Mutant Glioma: Median…
Michael Ciesielski, Phd @mjciesielski Of Roswell Park Comprehensive Cancer Center Discusses Latest Data On SurVaxM Vaccine: Doubled Progression Free Period,…
Hope Rugo, M.D., University Of California San Francisco discusses Talazoparib First Line Treatment. At ESMO Oncology Conference – Munich, Germany…
Hope Rugo, M.D., University Of California San Francisco discusses IMpassion130, Solar-1 Trial Data. At ESMO Oncology Conference – Munich, Germany…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Wolfgang Wick, MD, of the…
The NOA-16 trial is a multicenter, Phase I trial, which enrolled patients with newly diagnosed grade III and IV astrocytomas…